A Randomized, Double-Blind, Placebo-Controlled Phase III Trial With an Open-Label Extension to Evaluate the Efficacy and Safety of TQA3605 Tablets in Chronic Hepatitis B Virus-Infected Patients With Low-Level Viremia or Suboptimal Response After at Least 12 Months of NAs Therapy

This is a multicenter, randomized, double-blind, placebo-controlled Phase III study with an open-label extension. The purpose is to evaluate efficacy and safety in adult patients with chronic hepatitis B virus infection who have received at least 12 months of NAs therapy, to demonstrate that TQA3605 Tablets combined with oral nucleos(t)ide analogues can improve efficacy with satisfactory safety profile compared with oral nucleos(t)ide analogues alone in this population. Approximately 930 adult patients with chronic hepatitis B virus infection who have received at least 12 months of NAs therapy are planned to be enrolled in this study.

Start Date01 Sep 2026

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT07295873

/ CompletedPhase 1

A Single-Center, Open-Label, Single-Arm, Self-Controlled Phase I Clinical Study to Evaluate Drug-Drug Interactions of Hydronidone With Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide in Healthy Chinese Subjects

The proposed indication for Hydronidone Capsules is chronic hepatitis B-associated liver fibrosis, which in clinical practice typically requires concomitant use with antiviral agents for chronic hepatitis B. The commonly used chronic hepatitis B antiviral agents include Entecavir, Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF), and Tenofovir Amibufenamide (TMF).
This study aims to evaluate the drug-drug interaction (DDI) of Hydronidone Capsules 90 mg with Entecavir, Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF), and Tenofovir Amibufenamide (TMF) respectively in healthy participants, to inform the preparation of post-marketing labeling and the development of concomitant dosing regimens in clinical practice.

Start Date15 Mar 2026

Sponsor / Collaborator

Beijing Kangdini Pharmaceutical Co., Ltd.

NCT07345611

/ Not yet recruitingPhase 4IIT

Efficacy and Safety of Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3 to 6 Years With Chronic Hepatitis B in the Immune-Clearance Phase (B-Young-Cure-2): A Multicenter, Open-Label, Randomized Controlled Trial

This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with chronic hepatitis B.

Start Date11 Jan 2026

Sponsor / Collaborator

The First Affiliated Hospital of Zhengzhou University

[+3]

100 Clinical Results associated with Entecavir

100 Translational Medicine associated with Entecavir

100 Patents (Medical) associated with Entecavir

3,601

Literatures (Medical) associated with Entecavir

01 Dec 2026·JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Inhibitor screening identifies Entecavir as a promising candidate targeting human eIF4E to block cap-dependent translation in cancer: an integrated in silico and in vitro study

Article

Author: Gupta, Krishna Kant ; Nagasubramanian, Kishore ; Chandran, Sam Aldrin ; Vincent, Preethi

Eukaryotic translation initiation factor 4E (eIF4E) plays a critical role in cap-dependent translation by binding the 7-methylguanosine (m⁷G) cap at the 5' end of mRNAs, thereby regulating the synthesis of proteins essential for cell growth, survival, and proliferation. Under homeostatic conditions, eIF4E selectively translates a subset of mRNAs; however, in cancer, aberrant signaling leads to persistent activation of eIF4E, promoting tumor progression, metastasis, and resistance to therapy. Despite its clinical relevance, very few studies have explored direct targeting of eIF4E's cap-binding function using small molecules as a therapeutic strategy. In the present study, we adopted a multi-layered in silico and experimental pipeline to identify small-molecule inhibitors that can effectively disrupt human eIF4E activity. A library of over 400,000 compounds from the ZINC database was virtually screened using the Glide docking protocol in Schrödinger-Maestro. Compounds were shortlisted based on binding affinity and drug-likeness properties. Among the top hits, ZINC145267992, a nucleoside-like molecule, showed promising interaction with the cap-binding pocket of eIF4E. To overcome potential druggability limitations and improve clinical relevance, Entecavir (ETV), a clinically approved antiviral drug for hepatitis B and a structural analogue of ZINC145267992, was identified as a candidate for drug repurposing. Molecular dynamics simulations confirmed the stable interaction of ETV with eIF4E. Our findings not only reinforce the feasibility of targeting eIF4E in cancer but also demonstrate that repurposing FDA-approved drugs like Entecavir could offer a practical and efficient route to therapeutic intervention. This integrative approach opens new avenues for eIF4E-targeted strategies in oncology, aiming to selectively impair oncogenic translation.

01 Oct 2026·ANTIVIRAL RESEARCH

HBVZ10 exhibits robust in vivo potency and synergizes with entecavir to drive efficient cccDNA elimination and HBsAg seroclearance

Article

Author: Zhou, Yuanping ; Wu, Yukun ; Zoulim, Fabien ; Horrigan, Stephen ; Hu, Jianming ; Zhang, Bai-Hua ; Zhang, Yong-Yuan ; Luckenbaugh, Laura

BACKGROUND:

Current nucleos(t)ide analog (NA) therapies for chronic hepatitis B (CHB) fail to achieve a functional cure because they do not completely halt viral replication, allowing low-level virion release to continuously replenish the intrahepatic covalently closed circular DNA (cccDNA) pool. Emerging siRNA and antisense oligonucleotides (ASO) show promise but typically require baseline HBsAg levels below 1000 IU/mL to be effective. HBVZ10 is a novel therapeutic candidate designed for endogenous production of neutralizing anti-HBs antibodies using skeletal muscle cells.

METHODS:

We evaluated the in vivo potency of HBVZ10 and efficacy of combination with Entecavir (ETV) in immunodeficient mice with humanized livers. Primary endpoints included serum HBV DNA, HBsAg, and anti-HBs antibody titers, alongside intrahepatic relaxed circular DNA (rcDNA) and cccDNA levels.

RESULTS:

Following a single administration, HBVZ10-mediated anti-HBs titers rapidly rose and were maintained at ≥100,000 mIU/mL until termination (231 days). HBVZ10 monotherapy consistently suppressed serum HBV DNA down by 78-93% and HBsAg down by 80-90% over 170 days. The HBVZ10+ETV combination therapy induced HBsAg seroclearance in 88.9% (8/9) of mice, significantly outperforming ETV monotherapy (10%, 1/10; p = 0.001). Furthermore, the combination resulted in a 10-fold and 100-fold greater reduction in hepatic rcDNA and cccDNA, respectively, compared to ETV alone.

CONCLUSIONS:

HBVZ10 demonstrates robust in vivo potency through reducing massive HBsAg burden and creating the conditions for effectively neutralizing virions and blocking extracellular pathways for cccDNA replenishment. This capacity provides a critical pharmacological foundation for synergy when combined with intracellular inhibitors.

01 Sep 2026·AMERICAN JOURNAL OF GASTROENTEROLOGY

Long-Term Effectiveness of Tenofovir Alafenamide Versus Entecavir in Treatment-Naive Chronic Hepatitis B: A Real-World Evidence from the Global Alliance for the Study of Hepatitis B Virus

Article

Author: Ishikawa, Toru ; Toyoda, Hidenori ; Inoue, Kaori ; Nozaki, Akito ; Tsai, Pei-Chien ; Honda, Takashi ; Linden, Sovann ; Itokawa, Norio ; Kozuka, Ritsuzo ; Trinh, Huy ; Huang, Daniel Q. ; Wu, Chao ; Tsuji, Kunihiko ; Ito, Takanori ; Watanabe, Tsunamasa ; Huang, Jee-Fu ; Chau, Angela ; Liu, Joanne Kimiko ; Itobayashi, Ei ; Yu, Ming-Lung ; Tanaka, Yasuhito ; Gadano, Adrian ; Rui, Fajuan ; Yeh, Ming-Lun ; Dai, Chia-Yen ; Uojima, Haruki ; Li, Jie ; Ni, Wenjing ; Vutien, Philip ; Abe, Hiroshi ; Morimoto, Manabu ; Nguyen, Mindie H. ; Maeda, Mayumi ; Takaguchi, Koichi ; Enomoto, Masaru ; Huang, Chung-Feng ; Senoh, Tomonori ; Takahashi, Hirokazu ; Cheung, Ramsey ; Zhu, Yixuan ; Atsukawa, Masanori ; Lim, Seng Gee ; Chuang, Wan-Long ; Marciano, Sebastián

INTRODUCTION::

Although both tenofovir alafenamide (TAF) and entecavir (ETV) are recommended first-line treatments for chronic hepatitis B, comparative data on their effectiveness remain limited. We aim to compare their virologic (VR), biochemical (BR), and complete (CR) response rates.

METHODS::

This retrospective study enrolled treatment-naive chronic hepatitis B patients who initiated either TAF or ETV in 2016 or after across 22 international centers and evaluated their treatment response after balancing their characteristics using inverse probability treatment weighting and through Fine-Gray competing-risks analysis of the balanced cohort.

RESULTS::

The study included 1,605 patients (784 TAF and 821 ETV patients with significant background differences) of whom 1,553 (96.8%) were from Asia. Inverse probability treatment-weighting analysis yielded a total weighted cohort of 1,660 (822 TAF and 838 ETV patients with balanced characteristics). The 5-year cumulative VRs were high in both groups with a slightly higher rate in TAF patients (98.0% vs 93.9%, P < 0.001), and similar findings were found in a subgroup analysis by median hepatitis B virus (HBV) DNA (5.5 log IU/mL). However, there was no significant difference in the 5-year BR rates overall (93.7 vs 92.8%, P = 0.484) or by alanine aminotransferase (ALT) cutoff of 2× upper limit of normal. TAF patients had a slightly higher 5-year cumulative CR overall (94.9% vs 89.4%, P = 0.001) and in high HBV DNA (96.9% vs 87.9%, P < 0.001) or ALT ≥2× upper limit of normal patients (97.3% vs 90.6%, P < 0.001), but not in those with lower HBV DNA or ALT.

DISCUSSION::

BR rates were similar with ETV and TAF, while VR and CR were higher with TAF, although the difference was modest (<5% overall, 7%–9% in high HBV DNA or ALT groups). Antiviral selection between TAF vs ETV should be based mainly on cost, side effect profile, and patient preference.

News (Medical) associated with Entecavir

26 Aug 2026

·firstwordpharma.com

'Unprecedented' cure rate for GSK's hep B therapy prompts Japan approval

GSK's chronic hepatitis B (CHB) therapy notched its first-ever approval on Monday, nabbing a nod in Japan as its applications in the US, EU and China progress. Japan regulators greenlit Hibsago (bepirovirsen) as a functional cure for adults with a hepatitis B surface antigen (HBsAg) level of ≤3000 IU/mL who have received at least six months of prior nucleos(t)ide analogue (NA) therapy.The antisense oligonucleotide's clearance comes less than three months after GSK presented what it called "unprecedented" results from the Phase III B-Well 1 and B-Well 2 trials at the European Association for the Study of the Liver (EASL) congress.Pooled data from the two studies showed that patients with CHB who received once-weekly injections of Hibsago over the course of six months achieved a 19% functional cure response rate in the overall study population, a statistically significant result given the 0% cure rate for the placebo group, meeting the primary endpoint.Furthermore, in patients with low viral activity — defined as an HBsAg level of ≤1000 IU/mL, making up about 45% of all global CHB cases — the Hibsago group saw a functional cure rate of 26%. Current NA therapies like entecavir and tenofovir require daily dosing, with patients at risk of relapse if treatment is stopped. They're also associated with a functional cure rate of less than 1% (see – Spotlight On: GSK delivers historic win for hepatitis B patients).After the B-Well readouts, FirstWord spoke with Calvin Pan, a professor of medicine in the Division of Gastroenterology and Hepatology at New York University Grossman School of Medicine, who called the data "a very important milestone" for CHB. "There are no competitors with comparable functional cure rates right now," he said, but noted that GSK will likely have to run strong peer-to-peer campaigns in the US to raise patient and physician awareness of Hibsago (see – KOL Views Q&A: GSK's bepirovirsen is one small step for HBV patients, one giant leap for HBV therapy).A decision from the FDA on Hibsago is expected in "the coming months," GSK said Monday. The UK pharma in-licensed the drug from Ionis Pharmaceuticals in 2019, and recently inked a distribution deal with Sino Biopharmaceutical to help its commercialisation efforts in China.

Clinical ResultPhase 3License out/inDrug ApprovalOligonucleotide

16 Jun 2026

·www.scripps.edu

Calibr-Skaggs awarded $5.1M by NIH to develop long-acting hepatitis B virus therapy

A new program aims to replace a daily HBV drug with once-monthly—or even quarterly—injections for people managing both HIV and HBV. June 16, 2026 LA JOLLA, CA—Of the 1.2 million people living with HIV in the United States, approximately 10% are also infected with hepatitis B virus (HBV), a chronic condition that can be effectively controlled with the daily antiviral therapy entecavir. However, its real-world effectiveness is limited by the need for lifelong daily dosing, which presents a significant adherence challenge, particularly for individuals already managing complex HIV treatment regimens. Missed doses can lead to viral rebound, antiviral resistance and progressive liver damage. To address this critical gap, scientists at the Calibr-Skaggs Institute for Innovative Medicines—the drug discovery and development arm of Scripps Research—have been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a long-acting injectable (LAI) therapy for individuals co-infected with HIV and HBV. By reducing dosing frequency, the approach aims to improve adherence and deliver sustained HBV suppression for these patients. The new grant will provide up to $5.1 million over five years to support the development of a long-acting and pro-drug form of entecavir—a modified version that converts to the active drug inside the body. The goal of this new treatment is to replace daily oral pills with a once-monthly or once-quarterly injectable. Structured as a milestone-driven program, the funding will support optimization of the drug and carrier formulation, followed by safety, pharmacology and Investigational New Drug (IND)-enabling studies required to advance the candidate toward clinical evaluation. “Long-acting therapies have already transformed HIV care by helping improve treatment adherence, but people living with both HIV and HBV continue to face the challenge of maintaining daily HBV treatment,” says Anil Gupta, director of medicinal chemistry at Calibr-Skaggs and principal investigator on the new grant. “Because HIV can accelerate the liver damage associated with HBV, there remains a significant need for complementary treatment approaches that address both diseases together. Through this work, we aim to develop a long-acting form of entecavir that could be administered as infrequently as once every three months, with the potential to improve adherence and help patients more effectively manage both conditions.” To create the new long-acting drug, researchers are utilizing Calibr-Skaggs’ proprietary LAI platform: a technology designed to extend the duration and optimize the delivery of therapies ranging from small molecules such as entecavir to peptides and biologics. By reducing dosing frequency, the platform aims to improve treatment adherence, minimize side effects and lessen the burden of long-term therapy for patients. Beyond HBV, Calibr-Skaggs’ platform has supported programs in neurodegeneration, HIV, malaria, obesity and inflammatory diseases. One such therapy, MMV371—a long-acting prodrug version of atovaquone—is currently being evaluated in a Phase 1 clinical trial for malaria (NCT06558643). “This patient population faces a significant and ongoing treatment burden, where missed doses can contribute to worse outcomes and accelerated liver damage,” says Arnab Chatterjee, executive vice president of Calibr-Skaggs. “Our long-acting injectable platform was designed specifically for settings where extended drug delivery can make a meaningful difference. Across multiple disease areas, we’ve seen its potential to reduce dosing frequency and overall treatment burden, creating opportunities not only for greater convenience but also for potentially improved safety through lower cumulative therapy exposure over time.” For more information, contact press@scripps.edu See More News

Phase 1

15 Jun 2026

·www.einpresswire.com

ABL Diagnostics Announces Renewal of U.S. Patent (US 8,859,198 B2) for Hepatitis B Genotyping and Antiviral Resistance

Reinforcing long-term IP strength in molecular diagnostics and supporting global laboratory partners WOIPPY, FRANCE, June 15, 2026 / EINPresswire.com / -- ABL Diagnostics (FR001400AHX6 – “ABLD”), a specialist in molecular diagnostics, bioinformatics and decision-support solutions for infectious diseases, today announces that its parent company, Advanced Biological Laboratories (ABL) S.A. (Luxembourg), has successfully renewed a key United States patent, US 8,859,198 B2, reinforcing its long-term commitment to innovation in hepatitis B virus (HBV) genotyping and antiviral resistance analysis. Originally granted on October 14, 2014, the patent—titled “Detection and Use of Antiviral Resistance Mutations”—covers technologies for identifying HBV variants associated with reduced susceptibility to antiviral therapies. The invention remains active with an expected expiration around August 19, 2029. ( https://patents.google.com/patent/US8859198B2/en ). The renewal follows the latest USPTO maintenance milestone in 2026, ensuring continued protection of this strategic intellectual property. A Foundational Technology Supporting HBV Genotyping and Resistance Analysis: US 8,859,198 B2 covers the characterization and detection of hepatitis B viral mutations associated with altered response to widely used antiviral treatments such as lamivudine, adefovir, entecavir, or tenofovir. These capabilities support laboratory-based analysis of HBV genetic profiles and contribute to ongoing research and monitoring strategies in chronic hepatitis B. A Strong Licensing Model and Recurring revenue visibility: Through ABL S..A, this patented technology is licensed to leading reference laboratories worldwide. These laboratories leverage the patented methods to perform HBV genotyping and antiviral resistance analysis as part of their testing workflows. ABL’s technology supports a broad international network of diagnostic partners, strengthening its recurring licensing revenues and reinforcing its role in the global HBV diagnostics ecosystem. An Integrated Offering Combining Assays and Bioinformatics: ABL Diagnostics offers an integrated workflow combining molecular assays and bioinformatics tools designed to support HBV genomic analysis. 1. Molecular Assays (Wet Lab) ABL provides DeepChek ® Assays, targeted and whole-genome, designed for HBV genotyping, Detection of resistance-associated and vaccine escape mutations and Use with PCR amplification and sequencing workflows (Sanger or NGS). These assays enable laboratories to generate HBV sequence data from patient samples. 2. Bioinformatics and Data Interpretation Tools (Dry Lab) ABL provides a range of software tools for sequence analysis and interpretation such as DeepChek ® Software (HBV module), CE-IVD marked in the European Union, providing validated analysis and reporting functionalities in accordance with applicable IVD regulations and SeqHepB, an online data interpretation and research-use platform for Resistance-associated mutations identification, Genotype determination and resistance profiling and Standardized interpretation outputs generation. SeqHepB is intended for research or informational purposes only and is not a CE-IVD or FDA-cleared medical device. 3. An Integrated Workflow Approach Laboratories generate HBV sequence data using DeepChek ® Assays which may be analyzed using DeepChek ® Software (within its regulatory scope) and additional interpretation may be performed using SeqHepB. The availability and regulatory status of each component vary depending on the country. “The renewal of US 8,859,198 B2 highlights the enduring importance of HBV genotyping and resistance analysis in the context of long-term antiviral treatment,” said Ronan Boulmé, GRC Director at ABL Diagnostics. “ABL is proud to support laboratories worldwide with robust technologies and tools contributing to the understanding of HBV genetic variability and resistance patterns.” A Growing Market Driven by Molecular Diagnostics Adoption: The global demand for HBV genotyping continues to expand, driven by the significant burden of chronic hepatitis B, affecting nearly 296 million people worldwide, and the increasing adoption of molecular diagnostic technologies. The HBV genotyping market was valued at approximately USD 1.19 billion in 2024 and is projected to grow steadily. ( https://dataintelo.com/report/hbv-genotyping-market ). Genotyping and resistance analysis are increasingly used to Characterize viral genetic diversity, Monitor treatment-experienced patients and Support long-term disease management strategies. Evolving Therapeutics Reinforce the Role of Genomic Analysis: Current HBV treatments include nucleos(t)ide analogues such as entecavir and tenofovir (including tenofovir alafenamide), which have significantly improved viral suppression. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247%2825%2900004-7/fulltext However, as for HIV, Resistance-associated mutations may still emerge in certain contexts, Long-term monitoring remains important and New therapeutic approaches are under development. These trends reinforce the importance of tools and technologies enabling detailed viral genomic analysis. Regulatory Disclaimer : Certain components described, including SeqHepB, are not in vitro diagnostic medical devices and are not CE-IVD marked or FDA cleared. The DeepChek ® Software HBV module is CE-IVD marked in the European Union. Product availability and regulatory status may vary by country. About ABL Diagnostics (ABLD): ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers: - Molecular polymerase chain reaction (PCR) detection – UltraGene, and - Genotyping by DNA sequencing – DeepChek ® . ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion. ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. An expanding portfolio of microbiology products: - HIV – Drug resistance testing, including a whole genome kit. - SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions. - Microbiome and taxonomy – 16s/18s RNA-based analyses. - Other viral and bacterial targets – Comprehensive molecular assays. Integrated Solutions - Real-time syndromic PCR tests - Nadis ® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis. - MediaChek ® – Clinical Sample Collection Kits. ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology. Contact ABL Diagnostics SA Société anonyme au capital de 1 611 465,60 euros Headquarters : 72C route de Thionville - 57140 WOIPPY 552 064 933 R.C.S. METZ Tel : +33 (0)7 83 64 68 50 Email : info@abldiagnostics.com https://www.abldiagnostics.com/ Dr Sayada ABL Diagnostics SA +33 7 83 64 68 50 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Entecavir

External Link

KEGG	Wiki	ATC	Drug Bank
D04008	Entecavir	J05AF10	DB00442

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatitis B, Chronic	United States	Bristol Myers Squibb Co.	29 Mar 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Disease	Phase 3	United States	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Canada	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Hong Kong	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Indonesia	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Philippines	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Singapore	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Taiwan Province	Bristol Myers Squibb Co.	01 Dec 2004
Chronic Disease	Phase 3	Thailand	Bristol Myers Squibb Co.	01 Dec 2004
Hepatitis B	Phase 3	United States	Bristol Myers Squibb Co.	01 Sep 2002
Viremia	Phase 3	United States	Bristol Myers Squibb Co.	01 Sep 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02327416 (Pubmed \| Hepatol Int)	Phase 3	Hepatitis B, Chronic	249	Peginterferon alfa-2b + Entecavir	ylhszweofj(jjeynufrtk) = hhppordpaz beofbffvrc (lmiktsobal ) View more	Positive	09 Dec 2025
				Peginterferon alfa-2b + Entecavir + GM-CSF	ylhszweofj(jjeynufrtk) = qrhebwozkz beofbffvrc (lmiktsobal ) View more
AASLD2025	Not Applicable	Hepatitis B, Chronic	1,878	ETV/TAF	lxjxnhplzq(kdoypdcxny) = oeocfjngxt bejkdgvkqh (gdetbdiads ) View more	Positive	07 Nov 2025
				TMF	lxjxnhplzq(kdoypdcxny) = icgbhcpqtl bejkdgvkqh (gdetbdiads )
AASLD2024	Not Applicable	Hepatitis B, Chronic	15	Entecavir	uoakjnpuvy(krwbjxacmh) = kvgfdeakph znvagkfjhe (dhohndcwlc ) View more	Positive	15 Nov 2024
AASLD2024	Not Applicable	Hepatitis B, Chronic	6,696	Tenofovir alafenamide	wobinrdyst(fyyeokqdpu) = wfpajavlvd vfzdvsacoo (klbsvugzso ) View more	Negative	15 Nov 2024
AASLD2024	Not Applicable	Decompensated cirrhosis of liver	3,048	Entecavir or tenofovir (No excessive alcohol consumption)	bciebxbfat(sgsbnueheu) = mjbmkwqaqi mtctduftux (zjnvtzykcc ) View more	Positive	15 Nov 2024
				Entecavir or tenofovir (Excessive alcohol consumption)	iiteivsssa(rqwlcrmnsp) = uykimteaax esrocfywrb (nfsbgtrxsr ) View more
AASLD2024	Not Applicable	Hepatitis B, Chronic	1,384	Tenofovir alafenamide fumarate (TAF)	mkkdevqdpi(nurteyuxhf) = blnnaanibl ocxhvxthss (vzciuiwxbp ) View more	Positive	15 Nov 2024
				Entecavir (ETV)	mkkdevqdpi(nurteyuxhf) = yhrllpbwkt ocxhvxthss (vzciuiwxbp ) View more
AASLD2024	Not Applicable	Multiple Myeloma	109	Prophylactic antiviral therapy	sukqqfopiy(kwoyoenbdc) = whjpfzkodv qypldkjmuh (yxfebvjlyn ) View more	Positive	15 Nov 2024
				Non-antiviral treatment	codpcooyyx(xrlgycnzev) = wubxjbufjk bhnfgkaads (ruxzwrbhyd )
NCT04536337 (ALG-000184-201, EASL2024) Manual	Phase 1	Hepatitis B, Chronic	22	ALG-000184 + ETV	jnzydbdkhl(sdhwuggunj) = In a multiple regression model, baseline HBsAg (< or ≥4 log10 IU/ ml) and steady state plasma ALG-001075 exposure (AUC or Ctrough) statistically significantly predicted change from baseline in HBsAg at week 24 (p < 0.00018, R2 = 0.65). lyhdanirpp (pzhnfubymx ) View more	Positive	01 Jun 2024
				ALG-000184
NCT04536337 (ALG-000184-201, EASL2024) Manual	Phase 1	Hepatitis B, Chronic	22	ALG-000184 + Entecavir	uldazfksgd(jbkubqpzwo) = comjrjjdav wsjclcylni (xvmrfxtudu, 0.4) View more	Positive	01 Jun 2024
				ALG-000184	-
NCT03887702 (CTgov)	Phase 3	Hepatitis B \| Malignant Solid Neoplasm	4	Tenofovir Alafenamide+Tenofovir Disoproxil Fumarate+Entecavir (Arm 1 (TAF, TDF, Entecavir: Prophylactic))	fyfpfljvwp(wuwktnpviv) = sfbyuzlcnp rkfqlwpmip (unxegwqpsj, bwfqmezias - oxufwehqjn) View more	-	20 May 2024
				Tenofovir Alafenamide+Tenofovir Disoproxil Fumarate+Entecavir (Arm 2 (TAF, TDF, Entecavir: Upon Indication))	fyfpfljvwp(wuwktnpviv) = czqrkbytiy rkfqlwpmip (unxegwqpsj, eisqgltopz - yhxgmtvipo) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis